• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较随机尿蛋白肌酐比值与24小时尿蛋白用于蛋白尿评估的情况。

Comparison of spot urine protein creatinine ratio with 24 hour urine protein for estimation of proteinuria.

作者信息

Patil Pallavi, Shah Vinaya, Shah Bipin

出版信息

J Assoc Physicians India. 2014 May;62(5):406-10.

PMID:25438486
Abstract

The objective of our study was to evaluate and standardise the method of spot (random) urine protein creatinine ratio (UP/C) for estimation of proteinuria. The study contained 241 study participants in a tertiary care hospital inclusive of 208 cases and 33 normal volunteers. The 24 hour urine protein estimation was done on 24 hour urine samples and UP/C ratio was calculated on random urine samples. UP/C ratio and 24 hour urine protein estimation had strong correlation with r = 0.9 and p < 0.05 on Pearson's correlation analysis. Receiver operating characteristic analysis showed random UP/C ratio of 0.1171 reliably predicted 24 hour urine total protein equivalent of > 150 mg/24 hrs with sensitivity 100%, specificity 98.1%, positive likelihood ratio 53.5, and negative likelihood ratio 0. UP/C ratio of 3.2 reliably predicted nephrotic range proteinuria at 24 hour urine protein equivalent of > 3.5 g/24 hrs with sensitivity 80%, specificity 100%, positive likelihood ratio 154.4, and negative likelihood ratio 0.2. We conclude that spot/random UP/C ratio is a reliable, simple test to be introduced and adopted in routine practice for monitoring of macro proteinuria.

摘要

我们研究的目的是评估并标准化用于估计蛋白尿的随机尿蛋白肌酐比值(UP/C)方法。该研究纳入了一家三级护理医院的241名研究参与者,包括208例患者和33名正常志愿者。对24小时尿液样本进行24小时尿蛋白测定,并对随机尿液样本计算UP/C比值。经Pearson相关性分析,UP/C比值与24小时尿蛋白测定具有强相关性,r = 0.9且p < 0.05。受试者工作特征分析显示,随机UP/C比值为0.1171时可可靠预测24小时尿总蛋白当量>150 mg/24小时,敏感性为100%,特异性为98.1%,阳性似然比为53.5,阴性似然比为0。UP/C比值为3.2时可可靠预测24小时尿蛋白当量>3.5 g/24小时的肾病范围蛋白尿,敏感性为80%,特异性为100%得,阳性似然比为154.4,阴性似然比为0.2。我们得出结论,随机/即时UP/C比值是一种可靠、简便的检测方法,可引入并应用于常规实践中以监测大量蛋白尿。

相似文献

1
Comparison of spot urine protein creatinine ratio with 24 hour urine protein for estimation of proteinuria.比较随机尿蛋白肌酐比值与24小时尿蛋白用于蛋白尿评估的情况。
J Assoc Physicians India. 2014 May;62(5):406-10.
2
Comparison of 24-hour urinary protein and protein-to-creatinine ratio in the assessment of proteinuria.24小时尿蛋白与蛋白肌酐比值在蛋白尿评估中的比较
Saudi J Kidney Dis Transpl. 2009 May;20(3):443-7.
3
Predicting kidney transplantation outcomes using proteinuria ascertained from spot urine samples versus timed urine collections.使用即时尿液样本与定时尿液收集检测的蛋白尿预测肾移植结局。
Am J Kidney Dis. 2014 Dec;64(6):962-8. doi: 10.1053/j.ajkd.2014.07.027. Epub 2014 Oct 8.
4
Correlation between the protein/creatinine ratio in spot urine and 24-hour urine protein.尿标本蛋白/肌酐比值与 24 小时尿蛋白的相关性。
Nefrologia. 2012 Jul 17;32(4):494-501. doi: 10.3265/Nefrologia.pre2012.Apr.11300.
5
A comparison of spot urine protein-creatinine ratio with 24-hour urine protein excretion in women with preeclampsia.子痫前期女性随机尿蛋白肌酐比值与24小时尿蛋白排泄量的比较。
Iran J Kidney Dis. 2008 Jul;2(3):127-31.
6
Spot urine protein-to-creatinine ratio compared with 24-hour urinary protein in patients with kidney transplant.肾移植患者随机尿蛋白与肌酐比值与24小时尿蛋白的比较
Exp Clin Transplant. 2014 Aug;12(4):300-3.
7
Comparison of 24-hour urinary protein and protein-to-creatinine ratio in women with preeclampsia.比较先兆子痫女性 24 小时尿蛋白与尿蛋白/肌酐比值。
Eur J Obstet Gynecol Reprod Biol. 2013 Oct;170(2):368-71. doi: 10.1016/j.ejogrb.2013.07.024. Epub 2013 Aug 6.
8
Use of protein: creatinine ratio in a random spot urine sample for predicting significant proteinuria in diabetes mellitus.利用随机点尿样中的蛋白质:肌酐比值预测糖尿病中的显著蛋白尿。
Nepal Med Coll J. 2010 Jun;12(2):100-5.
9
Usage of spot urine protein to creatinine ratios in the evaluation of preeclampsia.随机尿蛋白与肌酐比值在子痫前期评估中的应用。
Am J Obstet Gynecol. 2007 May;196(5):465.e1-4. doi: 10.1016/j.ajog.2006.10.892.
10
Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis.随意收集的尿液中尿蛋白与肌酐比值是狼疮性肾炎中蛋白尿的可靠指标。
Rheumatology (Oxford). 2007 Apr;46(4):649-52. doi: 10.1093/rheumatology/kel360. Epub 2006 Oct 25.

引用本文的文献

1
Comparing estimated protein excretion rate and spot urinary protein-creatinine ratio in assessing urinary protein excretion in patients with kidney disease in China: a single center study.比较估计蛋白排泄率与随机尿蛋白肌酐比值在中国肾病患者中评估尿蛋白排泄的情况:一项单中心研究
Front Med (Lausanne). 2025 Mar 6;12:1517019. doi: 10.3389/fmed.2025.1517019. eCollection 2025.
2
Reliability of the spot urine protein/creatinine ratio for assessing proteinuria in patients with renal disease.尿蛋白/肌酐比值用于评估肾病患者蛋白尿的可靠性。
J Int Med Res. 2024 Sep;52(9):3000605241281874. doi: 10.1177/03000605241281874.
3
The correlation of spot urinary protein-to-creatinine ratio with 24-h urinary protein excretion in various glomerulopathies.
不同肾小球疾病中随机尿蛋白与肌酐比值与24小时尿蛋白排泄的相关性。
World J Nephrol. 2023 Dec 25;12(5):159-167. doi: 10.5527/wjn.v12.i5.159.
4
Comparison of three spot proteinuria measurements for pediatric nephrotic syndrome: based on the International pediatric Nephrology Association 2022 Guidelines.三种点尿蛋白测量方法在儿童肾病综合征中的比较:基于国际儿科肾脏病学会 2022 指南。
Ren Fail. 2023;45(2):2253324. doi: 10.1080/0886022X.2023.2253324. Epub 2023 Sep 19.
5
Estimation of 24 h Urine Protein Versus Spot Urine Protein Creatinine Ratio in Patients with Kidney Disease.肾病患者24小时尿蛋白与随机尿蛋白肌酐比值的评估
Indian J Clin Biochem. 2022 Jul;37(3):361-364. doi: 10.1007/s12291-020-00943-0. Epub 2021 Jan 25.
6
Comparison of 24-h Urine Protein, Urine Albumin-to-Creatinine Ratio, and Protein-to-Creatinine Ratio in IgA Nephropathy.IgA肾病中24小时尿蛋白、尿白蛋白与肌酐比值及蛋白与肌酐比值的比较
Front Med (Lausanne). 2022 Feb 28;9:809245. doi: 10.3389/fmed.2022.809245. eCollection 2022.
7
Optimization of 25% Sulfosalicylic Acid Protein-to-Creatinine Ratio for Screening of Low-Grade Proteinuria.用于筛查轻度蛋白尿的25%磺基水杨酸蛋白与肌酐比值的优化
Int J Anal Chem. 2021 Jan 28;2021:6688941. doi: 10.1155/2021/6688941. eCollection 2021.
8
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.二期、随机、双盲、多中心研究,评估 filgotinib 和 lanraplenib 在狼疮性膜性肾病患者中的安全性和疗效。
RMD Open. 2020 Dec;6(3). doi: 10.1136/rmdopen-2020-001490.